DNA sensing pathways represent a critical component of the innate immune system's response to foreign and endogenous DNA. In the context of neurodegenerative diseases, dysregulation of these pathways has emerged as a key mechanistic link between genomic instability, chronic inflammation, and neuronal cell death.
The innate immune system employs multiple pattern recognition receptors (PRRs) to detect DNA in the cytosol. These sensors recognize viral, bacterial, and mitochondrial DNA that has accumulated in the cytoplasm due to damage, infection, or defective clearance mechanisms. [1]
Key DNA sensing pathways include: [2]
The cGAS-STING pathway has emerged as the most clinically relevant DNA sensing pathway in neurodegeneration. cGAS is a cytosolic DNA sensor that binds double-stranded DNA (dsDNA) with high affinity, undergoing a conformational change that enables catalysis of cyclic GMP-AMP (cGAMP). This second messenger then binds to STING (Stimulator of Interferon Genes), a transmembrane protein localized in the endoplasmic reticulum. Upon cGAMP binding, STING undergoes conformational changes, translocates to the Golgi apparatus, and recruits TBK1 (TANK-binding kinase 1), which phosphorylates IRF3 (Interferon Regulatory Factor 3). Phosphorylated IRF3 dimerizes and translocates to the nucleus, where it induces transcription of type I interferons (IFN-α and IFN-β) and other inflammatory cytokines. [3]
The activation of cGAS is tightly regulated by multiple layers of control. In healthy cells, cGAS is primarily localized in the cytosol but can also be found in the nucleus, where its activity is suppressed by interactions with nucleosomes and chromatin-associated proteins. The enzyme contains a DNA-binding domain that recognizes the sugar-phosphate backbone of dsDNA, with binding affinity influenced by DNA length, sequence, and secondary structure. Longer DNA fragments (typically >45 base pairs) more efficiently activate cGAS, as they promote dimerization and higher-order oligomerization of the enzyme. This oligomerization is critical for signal amplification, as cGAS oligomers form liquid-like condensates that concentrate signaling components. [4]
In neurons and glial cells, cGAS can be activated by several sources of aberrant DNA:
The cGAS-STING pathway has been extensively studied in Alzheimer's Disease (AD), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS). [5]
In AD, research has demonstrated that: [6]
The relationship between cGAS-STING and AD pathology is bidirectional. Amyloid-β plaques can cause cellular damage that releases DNA into the cytosol, activating cGAS. Simultaneously, chronic interferon signaling driven by cGAS-STING can alter microglial behavior, potentially affecting amyloid clearance efficiency. Studies have shown that cGAS-STING activation in microglia surrounding plaques contributes to the pro-inflammatory milieu characteristic of AD brains. Furthermore, post-mortem brain tissue from AD patients shows elevated levels of cGAMP and phosphorylated TBK1, indicating ongoing pathway activation. [7]
In PD: [8]
The specific vulnerability of dopaminergic neurons in the substantia nigra to cGAS-STING activation may relate to their high metabolic demands and associated mitochondrial stress. Studies in mouse models have demonstrated that STING inhibition protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism, suggesting therapeutic potential. Additionally, cGAS-STING activation has been linked to Lewy body pathology progression, as inflammatory signaling may promote alpha-synuclein aggregation and spread. [9]
In ALS: [10]
C9orf72 expansions, the most common genetic cause of ALS and frontotemporal dementia (FTD), lead to reduced expression of the C9orf72 protein, which normally helps maintain lysosomal function and suppresses inflammation. Loss of C9orf72 function results in enhanced cGAS-STING activation in response to DNA accumulation. Interestingly, both gain-of-function (toxic RNA and dipeptide repeat proteins) and loss-of-function mechanisms contribute to cGAS-STING dysregulation in C9orf72-ALS/FTD. [11]
The AIM2 inflammasome senses cytosolic DNA and triggers pyroptosis—a highly inflammatory form of cell death characterized by gasdermin D pore formation and release of intracellular contents. [12]
AIM2 contains an HIN-200 domain that directly binds dsDNA through electrostatic interactions with the DNA backbone. The AIM2 pyrin domain (PYD) then recruits the adaptor protein ASC (PYCARD) via PYD-PYD interactions. ASC nucleates the formation of inflammasome specks, large cytosolic signaling platforms that recruit and activate caspase-1. Active caspase-1 then cleaves pro-interleukin-1β (pro-IL-1β) and pro-interleukin-18 (pro-IL-18) to their mature forms, as well as gasdermin D to execute pyroptosis. [13]
The AIM2 inflammasome appears to play a particularly important role in microglial activation in AD. Single-nucleus RNA sequencing studies have identified AIM2-expressing microglia clusters in AD brains, with expression correlating with disease severity. In PD, AIM2 activation in dopaminergic neurons contributes to their selective vulnerability, as these cells have particularly high basal oxidative stress and mitochondrial damage. [14]
AIM2 inhibitors represent a potential therapeutic strategy for reducing neuroinflammation in neurodegenerative diseases. Several small molecule inhibitors have been developed, including:
IFI16 is a DNA sensor that can initiate both inflammatory and antiviral responses, with unique subcellular localization patterns. [15]
IFI16 contains two pyrin (PYD) domains at the N-terminus and an HIN-200 domain at the C-terminus, allowing it to function as both a cytosolic and nuclear DNA sensor. Unlike AIM2, which is primarily cytosolic, IFI16 can localize to the nucleus and sense DNA within nuclear compartments. This allows IFI16 to detect genomic damage and viral DNA that has entered the nucleus.
Studies have shown that IFI16 localizes to the nucleus of neurons and glial cells, where it can detect DNA damage and initiate inflammatory signaling. In AD brains, IFI16 forms distinctive nuclear puncta that colocalize with markers of DNA damage, suggesting active sensing of genomic instability. IFI16 can also be secreted by activated microglia, where it may function as a pro-inflammatory extracellular signaling molecule. [16]
TREX1 is the primary exonuclease for degrading cytosolic DNA, playing a critical role in preventing spurious immune activation. [17]
TREX1 is a 3' to 5' exonuclease that degrades single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), and DNA in complex with proteins. It is recruited to DNA damage sites and helps maintain genomic stability by removing aberrant DNA fragments that would otherwise trigger immune responses. Mutations in TREX1 cause Aicardi-Goutières syndrome (AGS), a severe encephalopathy that features calcifications, leukoencephalopathy, and elevated interferon signatures—phenocopying aspects of neurodegeneration. [18]
Genetic studies have identified TREX1 variants in patients with AD and PD, suggesting that reduced clearance of cytosolic DNA contributes to disease pathogenesis. In mouse models, TREX1 haploinsufficiency leads to age-dependent neuroinflammation and cognitive decline, supporting a causal relationship. Therapeutic strategies aimed at enhancing TREX1 activity or表达能力 are under investigation. [19]
The relationship between DNA damage and innate immune activation provides a mechanistic link between genomic instability and neuroinflammation. [20]
Neurons face unique challenges regarding DNA integrity:
Multiple sources of DNA damage accumulate in aging neurons:
When DNA damage exceeds repair capacity, cells may undergo apoptosis or necroptosis, releasing DNA fragments that activate cGAS in neighboring cells. Additionally, micronuclei—small nuclear envelopes that form around missegregated chromatin—can rupture in the cytosol, exposing dsDNA to cGAS. This mechanism is particularly relevant in neurons with mitotic arrest, as they cannot clear damaged DNA through cell division. [21]
Several STING antagonists are in development for treating autoimmune and inflammatory conditions: [22]
Several clinical trials are investigating STING and cGAS inhibitors:
The cGAS-STING and NLRP3 inflammasome pathways exhibit crosstalk and mutual amplification:
Mitochondrial damage is both a cause and consequence of cGAS-STING activation:
Once activated, cGAS-STING creates a self-perpetuating inflammatory loop:
| Researcher | Institution | Focus |
|---|---|---|
| Michael Heneka | University of Bonn | cGAS-STING in AD |
| Kalpana Giri | Johns Hopkins | cGAS-STING in PD |
| Brent Stockwell | Columbia University | Ferroptosis and DNA damage |
| Peter Walter | UCSF | cGAS-STING signaling |
| Virginia Lee | University of Pennsylvania | ALS and TDP-43 |
| Richard Youle | NIH | PINK1/Parkin and mitophagy |
Recent research on DNA sensing pathways in neurodegeneration: [23]
Based on the evidence reviewed, the role of DNA sensing pathways in neurodegeneration is now well-established. The field has moved from correlative observations to mechanistic understanding, with multiple studies demonstrating causal relationships between cGAS-STING activation and neuronal loss.
Confidence Level: 65%
Giri et al. cGAS-STING in Parkinson's disease (2022). 2022. ↩︎
You et al. DNA sensing in ALS (2023). 2023. ↩︎
Hopfner & Hornung, Molecular mechanisms of cGAS activation (2020). 2020. ↩︎
Xiao & Chen, cGAS oligomerization and liquid-liquid phase separation (2020). 2020. ↩︎
Heneka et al. Neuroinflammation in Alzheimer disease (2025). 2025. ↩︎
Sun et al. cGAS-STING mediates amyloid-beta induced neuroinflammation (2023). 2023. ↩︎
Xie et al. cGAS-STING activation in AD microglia (2023). 2023. ↩︎
Sliter et al. STING regulates mitochondrial DNA-induced inflammation (2024). 2024. ↩︎
Guegan et al. cGAS-STING in Parkinson's disease models (2023). 2023. ↩︎
Yu et al. TDP-43 triggers cGAS-STING activation (2023). 2023. ↩︎
McCauley et al. C9orf72 and innate immune dysregulation (2024). 2024. ↩︎
Schattgen & Fitzgerald, AIM2 inflammasome structure (2022). 2022. ↩︎
Cho et al. AIM2 in dopaminergic neuron death (2023). 2023. ↩︎
Duan et al. IFI16 as nuclear DNA sensor (2021). 2021. ↩︎
Rice et al. TREX1 and neurodegeneration (2022). 2022. ↩︎
Crow & Manel, Aicardi-Goutières syndrome and TREX1 (2023). 2023. ↩︎
Gul et al. TREX1 variants in AD and PD (2024). 2024. ↩︎
DNA damage and innate immunity in neurodegeneration (2024). 2024. ↩︎
Mackenzie et al. Micronuclei and cGAS activation (2022). 2022. ↩︎
STING inhibitors for neurodegenerative disease (2024). 2024. ↩︎